Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lipid nanoparticle encapsulated MYC-targeting mRNA-based agent OTX-2002

A lipid nanoparticle (LNP)-based formulation consisting of a biscistronic mRNA that encodes two independent epigenomic controllers targeting the proto-oncogene MYC (c-Myc), with potential antineoplastic activity. Upon administration of LNP encapsulated MYC-targeting mRNA-based agent OTX-2002, the lipid formulation promotes the uptake by tumor cells. The biscistronic mRNA is then translated by the cellular protein translation machinery to produce two independent epigenomic controllers consisting of a DNA binding domain and an epigenetic effector protein. The two epigenomic controllers bind to regulatory regions on the MYC insulated genomic domain (IGD), a DNA loop bound by CTCF (CCCTC-binding factor). This downregulates MYC expression pre-transcriptionally, which may inhibit proliferation in susceptible tumor cells. MYC, a proto-oncogene overexpressed in a variety of cancers, plays a role in the regulation of transcription and cell proliferation.
Synonym:LNP encapsulated MYC-targeting mRNA-based agent OTX-2002
Code name:OTX 2002
OTX-2002
OTX2002
Search NCI's Drug Dictionary